Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling - PubMed
9 hours ago
- #liquid biopsy
- #colorectal cancer
- #precision medicine
- Liquid biopsy, through circulating tumour DNA (ctDNA), is used to characterize tumour molecular heterogeneity in colorectal cancer (CRC).
- It aids in identifying actionable targets for precision medicine and detecting genomic drivers of drug resistance in metastatic CRC.
- Liquid biopsy-based ctDNA analysis is validated for detecting minimal residual disease (MRD) post-locoregional treatment, improving prognosis and adjuvant therapy tailoring.
- Methodological advancements from PCR to next-generation sequencing enable comprehensive genomic profiling (CGP), enhancing understanding of cancer molecular complexity.
- Liquid biopsy-based CGP provides a dynamic view of CRC molecular heterogeneity, guiding personalized and adaptive treatments.
- The review discusses current and potential roles of liquid biopsy in managing metastatic CRC and refining locoregional CRC treatment.